Contractors passing the gateway criteria will receive a Quality Payment if they meet one or more of the quality criteria listed in the table below. Each criterion is designated a number of points and the total number of points that each contractor can qualify for is 100.
A written patient safety report (updated since 29 June 2018, i.e. the last review date or covering the last year if not previously claimed) at premises level available for inspection at review point covering analysis of incidents and incident patterns (taken from an ongoing log), evidence of sharing learning locally and nationally, and actions taken in response to national patient safety alerts; and
Demonstrably, the pharmacy contractor actively identifies and manages the risks at premises level associated with specified look-alike sound-alike errors (LASA) identified from the National Reporting and Learning System NRLS)**. Demonstrably, the pharmacy contractor has put in place actions to prevent these, for example physical separation, staff awareness raising, visual warnings, tags or labels on shelving, fatigue reduction strategies, enhanced checking procedures for these medicines.
Demonstrably, the pharmacy contractor uploads any LASA incident reports to the NRLS and keeps a record for confirmation of this activity at the pharmacy premises or within any electronic reporting system used by the contractor. In the description of what happened in the NRLS report, the contractor must include the text ‘LASA’ as a unique identifier to facilitate future national learning.
** NHS Improvement top combinations by likelihood and harm caused – propranolol and prednisolone, amlodipine and amitriptyline, carbamazepine and carbimazole, azathioprine and azithromycin, atenolol and allopurinol.
On the day of the review, 80% of all registered pharmacy professionals working at the pharmacy have satisfactorily completed the CPPE Risk Management training; and
the pharmacy has available for inspection at the review point, at premises level, an example of a risk review that the pharmacy team at the premises have drawn up for a risk in that pharmacy that has been identified and prioritised with identified risk minimisation actions that the pharmacy team is taking.
|Patient Safety||On the day of the review the pharmacy must have completed the audit of non-steroidal anti-inflammatory drugs and gastro-protection for patients 65 or over, notified the patient’s GP where professional concerns were identified, share their anonymised data with NHS England and incorporated the learning of the audit into future practice.||20|
On the day of the review the pharmacy is a Healthy Living Pharmacy level 1 (self-assessment) and;
80% of staff working at the pharmacy (including pharmacy professionals that provide healthcare advice to the public have successfully completed the CPPE children’s oral health training assessment.
|Digital/Urgent Care||On the day of the review, the pharmacy’s NHS 111 Directory of Services entry is up to date.||2.5|
On the day of the review, the pharmacy can show evidence of asthma patients, for whom more than 6 short acting bronchodilator inhalers were dispensed without any corticosteroid inhaler within a 6 month period, have since 29th June 2018 (i.e. the last review date) been referred to an appropriate health care professional for an asthma review; and
Can evidence that they have ensured that all children aged 5-15 years prescribed an inhaled corticosteroid for asthma have a spacer device where appropriate and have a personalised asthma action plan. Refer to an appropriate healthcare professional where this is not the case.
|Workforce||On the day of the review, 80% of all pharmacy staff working in patient facing roles are trained ‘Dementia Friends’.||2.5|
|Total number of points: 100|